Cover Image
市場調查報告書

百日咳:開發中產品分析

Pertussis (Whooping Cough) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 192770
出版日期 內容資訊 英文 104 Pages
訂單完成後即時交付
價格
Back to Top
百日咳:開發中產品分析 Pertussis (Whooping Cough) - Pipeline Review, H1 2016
出版日期: 2016年06月15日 內容資訊: 英文 104 Pages
簡介

所謂百日咳是傳染性極強的呼吸疾病。是由百日咳菌這個細菌所引起。常見的症狀有鼻涕、鼻塞、噴嚏、充血、眼淚、乾咳等。治療方法包含抗生素等。

本報告提供百日咳治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

百日咳概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

治療藥的開發企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Beijing Tiantan Biological Products Co., Ltd.
  • Bharat Biotech International Limited
  • Biological E. Limited
  • Boryung Pharmaceutical Co., Ltd.
  • 第一三共
  • DBV Technologies S.A.
  • GlaxoSmithKline Plc
  • Green Cross Corporation
  • ILiAD Biotechnologies, LLC
  • Indian Immunologicals Limited
  • LG Life Science LTD.
  • NanoBio Corporation
  • Panacea Biotec Limited
  • Sanofi Pasteur SA
  • Serum Institute of India Limited
  • Sinovac Biotech Ltd.
  • Synthetic Biologics, Inc.
  • Zydus Cadila Healthcare Limited

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8170IDB

Summary

Global Markets Direct's, 'Pertussis (Whooping Cough) - Pipeline Review, H1 2016', provides an overview of the Pertussis (Whooping Cough) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pertussis (Whooping Cough), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pertussis (Whooping Cough) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pertussis (Whooping Cough)
  • The report reviews pipeline therapeutics for Pertussis (Whooping Cough) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Pertussis (Whooping Cough) therapeutics and enlists all their major and minor projects
  • The report assesses Pertussis (Whooping Cough) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Pertussis (Whooping Cough)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Pertussis (Whooping Cough)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pertussis (Whooping Cough) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Therapeutics Development
    • Pipeline Products for Pertussis (Whooping Cough) - Overview
    • Pipeline Products for Pertussis (Whooping Cough) - Comparative Analysis
  • Pertussis (Whooping Cough) - Therapeutics under Development by Companies
  • Pertussis (Whooping Cough) - Therapeutics under Investigation by Universities/Institutes
  • Pertussis (Whooping Cough) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Pertussis (Whooping Cough) - Products under Development by Companies
  • Pertussis (Whooping Cough) - Products under Investigation by Universities/Institutes
  • Pertussis (Whooping Cough) - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co., Ltd
    • Beijing Tiantan Biological Products Co., Ltd.
    • Bharat Biotech International Limited
    • Biological E. Limited
    • Boryung Pharmaceutical Co., Ltd.
    • Daiichi Sankyo Company, Limited
    • DBV Technologies S.A.
    • GlaxoSmithKline Plc
    • Green Cross Corporation
    • ILiAD Biotechnologies, LLC
    • Indian Immunologicals Limited
    • LG Life Science LTD.
    • NanoBio Corporation
    • Panacea Biotec Limited
    • Sanofi Pasteur SA
    • Serum Institute of India Limited
    • Sinovac Biotech Ltd.
    • Synthetic Biologics, Inc.
    • Zydus Cadila Healthcare Limited
  • Pertussis (Whooping Cough) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole-cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole-cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + poliovirus + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (hepatitis B + pertussis) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bladder cancer + pertussis + tuberculosis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diphtheria + pertussis(acellular) + tetanus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Eupenta - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GC-3111A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBVD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pertussis (acellular) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pertussis (acellular) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pertussis (acellular) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pertussis (whole-cell) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pertussis [strain BPZE1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pertussis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pertussis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pertussis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SYN-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VN-0103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VN-0105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pertussis (Whooping Cough) - Dormant Projects
  • Pertussis (Whooping Cough) - Discontinued Products
  • Pertussis (Whooping Cough) - Product Development Milestones
    • Featured News & Press Releases
      • Mar 21, 2016: BE Receives an Order from Govt. of India to Supply Liquid Pentavalent Vaccines
      • Oct 21, 2015: Grant Awarded to Synthetic Biologics' Academic Collaborator to Fund Further Evaluation of Monoclonal Antibody for the Prevention of Whooping Cough
      • Jun 10, 2015: Key Scientific Data Demonstrating that Epicutaneous Administration May Reactivate Protective Immunity against Pertussis in an experimental model published in Vaccine
      • Apr 27, 2015: Posters at ECCMID 2015 Highlight Preclinical Data from Synthetic Biologics' Novel SYN-005 Monoclonal Antibody Combination for the Treatment and Prophylaxis of Whooping Cough (Pertussis)
      • Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta
      • Mar 02, 2015: Synthetic Biologics Announces Two Poster Presentations of Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at ECCMID 2015
      • Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program
      • Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine
      • Sep 12, 2014: Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis)
      • Sep 08, 2014: Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program
      • Aug 19, 2014: Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC
      • Aug 12, 2014: Synthetic Biologics Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at 54th ICAAC
      • Jul 21, 2014: Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough at Gordon Research Conference
      • Apr 23, 2014: Synthetic Biologics' Reports Preclinical Data to Support Clinical Development of Novel Pertussis Therapeutic
      • Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Pertussis (Whooping Cough), H1 2016
  • Number of Products under Development for Pertussis (Whooping Cough) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Pertussis (Whooping Cough) - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016
  • Pertussis (Whooping Cough) - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2016
  • Pertussis (Whooping Cough) - Pipeline by Bharat Biotech International Limited, H1 2016
  • Pertussis (Whooping Cough) - Pipeline by Biological E. Limited, H1 2016
  • Pertussis (Whooping Cough) - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2016
  • Pertussis (Whooping Cough) - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Pertussis (Whooping Cough) - Pipeline by DBV Technologies S.A., H1 2016
  • Pertussis (Whooping Cough) - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Pertussis (Whooping Cough) - Pipeline by Green Cross Corporation, H1 2016
  • Pertussis (Whooping Cough) - Pipeline by ILiAD Biotechnologies, LLC, H1 2016
  • Pertussis (Whooping Cough) - Pipeline by Indian Immunologicals Limited, H1 2016
  • Pertussis (Whooping Cough) - Pipeline by LG Life Science LTD., H1 2016
  • Pertussis (Whooping Cough) - Pipeline by NanoBio Corporation, H1 2016
  • Pertussis (Whooping Cough) - Pipeline by Panacea Biotec Limited, H1 2016
  • Pertussis (Whooping Cough) - Pipeline by Sanofi Pasteur SA, H1 2016
  • Pertussis (Whooping Cough) - Pipeline by Serum Institute of India Limited, H1 2016
  • Pertussis (Whooping Cough) - Pipeline by Sinovac Biotech Ltd., H1 2016
  • Pertussis (Whooping Cough) - Pipeline by Synthetic Biologics, Inc., H1 2016
  • Pertussis (Whooping Cough) - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pertussis (Whooping Cough) - Dormant Projects, H1 2016
  • Pertussis (Whooping Cough) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Pertussis (Whooping Cough), H1 2016
  • Number of Products under Development for Pertussis (Whooping Cough) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top